QUOTE AND NEWS
Benzinga  Jul 29  Comment 
In a report rolled out Wednesday, Roth Capital analysts Joseph Pantginis and Assaf Vestin reiterated a Buy rating and $135.00 price target on shares of Ligand Pharmaceuticals Inc. (NASDAQ: LGND), after partner Viking Therapeutics Inc (NASDAQ:...
newratings.com  Jul 24  Comment 
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) announces the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency (EMA) adopted a positive opinion for Revolade (eltrombopag), a Novartis product, for...
GenEng News  Jul 14  Comment 
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials. One therapy is a vaccine that targets a structure on the outside of cancer cells, while the...
Forbes  Jul 1  Comment 
Ligand CEO John Higgins was brought in by raider Dan Loeb to slash costs at a bloated biotech firm. Seven years later he's still there, running a lean, mean cash machine.
Benzinga  Jun 19  Comment 
In a report published Friday, Cantor Fitzgerald analyst Irina Rivkind Koffler maintained a Hold rating on Ligand Pharmaceuticals Inc. (NASDAQ: LGND), while raising the price target from $86 to $93. While the stock appears to be “fairly...
Benzinga  Jun 15  Comment 
Analysts at FBR Capital downgraded EMC Corporation (NYSE: EMC) from Outperform to Market Perform. The price target for EMC has been lowered from $31.00 to $28.00. EMC shares closed at $27.07 on Friday. Analysts at Deutsche Bank downgraded Ligand...
newratings.com  Jun 12  Comment 
BASEL (dpa-AFX) - Ligand Pharmaceuticals Incorporated (LGND) announced that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta (eltrombopag), a Novartis product, for the treatment of children six years and...
newratings.com  Jun 8  Comment 
THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) has completed patient enrollment in the study, dubbed FOURIER outcomes trial, which is designed to evaluate if its investigational product Repatha in combination with statin therapy reduces the risk of...





You may also be interested in articles related to Ligand Pharmaceuticals (LGND):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki